JPRN-jRCT2080221640已完成4 期
Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 640
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Documented progression from most recent line of therapy.
- •1-3 prior lines of therapy.
- •Measurable disease.
- •Life expectancy 3 months and more.
- •Prior treatment with Lenalidomide permitted if:
- •1.Best response achieved was more than Partial Response (PR).
- •2.Patient was not refractory.
- •3.Patient did not discontinue due to a Grade 3 and more related adverse event.
- •4.Subject did not receive more than 9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progression
排除标准
- •Subjects with non-secretory or oligo-secretory or serum free light-chain only myeloma.
- •Active plasma cell leukemia.
- •Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C.
研究者
相似试验
进行中（未招募）
1 期
Trial of Lenalidomide/dexamethasone With or Without Elotuzumab inSubjects with Previously Untreated Multiple Myeloma.EUCTR2010-022445-20-ESBristol-Myers Squibb International Corporation748
进行中（未招募）
1 期
Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma.EUCTR2010-022445-20-IEBristol-Myers Squibb International Corporation862
进行中（未招募）
1 期
Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma.EUCTR2010-022445-20-ITBRISTOL-M.SQUIBB862
进行中（未招募）
1 期
Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma.ntreated Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000054086EUCTR2010-022445-20-HUBristol-Myers Squibb International Corporation862
进行中（未招募）
1 期
A Phase 3 Relapsed or Refractory Multiple Myeloma - Open label with or without Elotuzumab.Relapsed or Refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2010-020347-12-BEBristol-Myers Squibb International Corporation640